Dexamethasone in Hospitalized Patients with Covid-19 (RECOVERY)
|
Design
|
Randomized, controlled, open-label, adaptive, platform trial
N=6,425
|
Objective
|
To evaluate the effects of dexamethasone in patients hospitalized with COVID-19
|
Study Groups
|
Dexamethasone (n=2,104)
Usual care (n=4,321)
|
Inclusion Criteria
|
Clinically suspected or laboratory-confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trail |
Exclusion Criteria
|
Dexamethasone considered either indicated or contraindicated, dexamethasone unavailable at the hospital at time of enrollment |
Methods
|
Eligible patients were assigned 2:1 to either usual standard of care or usual standard of care plus dexamethasone 6 mg (either PO or IV) once daily for up to 10 days (or discharge, if sooner). Participants could also be randomized to other arms of the RECOVERY trial, but these treatments are not discussed in these results.
|
Duration
|
Intervention: up to 10 days
Follow-up: 28 days
|
Outcome Measures
|
Primary outcome: all-cause mortality within 28 days of randomization
Secondary outcomes: time to discharge from hospital (within 28 days), subsequent receipt of invasive mechanical ventilation (including extra-corporeal membrane oxygenation) or death (among patients not receiving invasive mechanical ventilation at randomization)
|
Baseline Characteristics
|
|
Dexamethasone (n=2,104)
|
Usual care (n=4,321)
|
|
Age, years
|
66.9±15.4 |
65.8±15.8 |
|
Female
|
766 (36%) |
1,572 (36%) |
|
White
|
1,550 (74%) |
3,139 (73%) |
|
Days since symptom onset (IQR)
|
8 (5–13) |
9 (5–13) |
|
Days since hospitalization (IQR)
|
2 (1–5) |
2 (1–5) |
|
IQR=interquartile range |
Results
|
|
Dexamethasone (n=2,104)
|
Usual care (n=4,321)
|
Risk Ratio (95% CI)
|
Death at 28 days
No oxygen
Oxygen only
Invasive mechanical ventilation
|
482 (22.9%)
89/501 (17.8%)
298/1,279 (23.3%)
95/324 (29.3%)
|
1,110 (25.7%)
145/1,034 (14.0%)
682/2,604 (26.2%)
283/683 (41.4%)
|
0.83 (0.75–0.93)
1.19 (0.92–1.55)
0.82 (0.72–0.94)
0.64 (0.51–0.81)
|
Discharged from hospital within 28 days
|
1,416 (67.3%) |
2,748 (63.6%) |
1.10 (1.03–1.17) |
Invasive mechanical ventilation or death
|
462/1,780 (26.0%) |
1,003/3,638 (27.6%) |
0.93 (0.85–1.01) |
Invasive mechanical ventilation
|
110/1,780 (6.2%) |
298/3,638 (8.2%) |
0.79 (0.64–0.97) |
Death*
|
387/1,780 (21.7%) |
827/3,638 (22.7%) |
0.93 (0.84–1.03) |
Successful cessation of invasive mechanical ventilation
|
160/324 (49.4%) |
268/683 (39.2%) |
1.47 (1.20–1.78) |
Of those allocated to dexamethasone, 95% received at least one dose and they were treated for a median of 6 days. This is in contrast to 7% of the usual care group who received at least one dose of dexamethasone.
*excluded those on invasive mechanical ventilation at randomization
CI=confidence interval
|
Adverse Events
|
Common Adverse Events: not reported
|
Serious Adverse Events: Hyperglycemia, gastrointestinal hemorrhage, psychosis
|
Study Author Conclusions
|
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
|
InpharmD Researcher Critique
|
The size was large enough to collect enough data for the study. Information on physiologic, laboratory, or virologic measures were not collected.
This trial provides evidence that dexamethasone 6 mg once daily for up to 10 days reduced 28-day mortality among patients receiving respiratory support. Patients not receiving respiratory support saw no benefit (and the possibility of harm).
Approximately 7% of the patients were crossed over, as some of the usual care also involved dexamethasone. This was also an open-label study in a relatively sick population.
|